Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd News
May 9, 2025 - businesswire.com
LSB Industries, Inc. to Participate in UBS Energy Transition and Decarbonization Conference on Wednesday, May 14th
Apr 29, 2025 - businesswire.com
LSB Industries, Inc. Reports Operating Results for the 2025 First Quarter
Apr 23, 2025 - prnewswire.com
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
Apr 15, 2025 - businesswire.com
LSB Industries, Inc. Schedules 2025 First Quarter Results Release for Tuesday, April 29th and Conference Call for Wednesday, April 30th
LakeShore Biopharma Co., Ltd Quantitative Score
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
LakeShore Biopharma Co., Ltd Earnings & Revenue
LakeShore Biopharma Co., Ltd Financials
Table Compare
Compare LSB metrics with: | |||
|---|---|---|---|
Earnings & Growth | LSB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LSB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LSB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LSB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
LakeShore Biopharma Co., Ltd Income
LakeShore Biopharma Co., Ltd Balance Sheet
LakeShore Biopharma Co., Ltd Cash Flow
LakeShore Biopharma Co., Ltd Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
LakeShore Biopharma Co., Ltd Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
LakeShore Biopharma Co., Ltd Executives
| Name | Role |
|---|---|
| Dr. Yuan Liu Ph.D. | Head of Vaccine Research |
| Mr. Wang Xu | Chief Executive Officer & Director |
| Ms. Rui Yu M.B.A., M.S. | Chief Financial Officer & Director |
| Dr. Zenaida Reynoso Mojares M.D. | Chief Medical Officer |
| Ms. Zhiyuan Ran | Head of Medical & Marketing Department |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Yuan Liu Ph.D. | Head of Vaccine Research | 1987 | -- | |
| Mr. Wang Xu | Chief Executive Officer & Director | Male | 1971 | -- |
| Ms. Rui Yu M.B.A., M.S. | Chief Financial Officer & Director | Female | 1975 | -- |
| Dr. Zenaida Reynoso Mojares M.D. | Chief Medical Officer | 1959 | -- | |
| Ms. Zhiyuan Ran | Head of Medical & Marketing Department | Female | -- |